Daily News

Daily News

Effects of vitamin D supplementation on cognitive function and blood amyloid-related biomarkers in older adults with Alzheimer’s disease

Clinical Trials Daily

2019 NOV 28 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Data detailed on Neurodegenerative Diseases and Conditions - Alzheimer Disease have been presented. According to news reporting out of Tianjin, People’s Republic of China, by NewsRx editors, research stated, “Our study aimed to assess the effect of a 12-month vitamin D supplementation on cognitive function and amyloid beta (Ab)-related biomarkers in subjects with Alzheimer’s disease (AD). This was a randomised, double-blind, placebo-controlled trial. 210 AD patients were randomly divided into intervention and control groups.”

Financial support for this research came from National Natural Science Foundation of China.

Our news journalists obtained a quote from the research from Tianjin Medical University, “Participants received 12-month 800 IU/day of vitamin D or starch granules as placebo. Tests of cognitive performance and Ab-related biomarkers were measured at baseline, 6 months and 12 months. Repeated-measures analysis of variance showed significant improvements in plasma Ab42, APP, BACE1, APPmRNA, BACE1mRNA (p <0.001) levels and information, arithmetic, digit span, vocabulary, block design and picture arrange scores (p <0.05) in the intervention group over the control group. According to mixed-model analysis, vitamin D group had significant increase in full scale IQ during follow-up period (p <0.001). Daily oral vitamin D supplementation (800 IU/day) for 12 months may improve cognitive function and decrease Ab-related biomarkers in elderly patients with AD.”

According to the news editors, the research concluded: “Larger scale longer term randomised trials of vitamin D are needed.”

For more information on this research see: Effects of vitamin D supplementation on cognitive function and blood Ab-related biomarkers in older adults with Alzheimer’s disease: a randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery, & Psychiatry, 2019;90(12):jnnp-2018-320199. Journal of Neurology, Neurosurgery, & Psychiatry can be contacted at: B M J Publishing Group, British Med Assoc House, Tavistock Square, London WC1H 9JR, England.

Our news journalists report that additional information may be obtained by contacting F. Ma, Dept. of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, People’s Republic of China. Additional authors for this research include J. Hu, X. Huo, R. Miao, Y. Zhang and F. Ma.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1136/jnnp-2018-320199. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the Journal of Neurology, Neurosurgery, & Psychiatry is: B M J Publishing Group, British Med Assoc House, Tavistock Square, London WC1H 9JR, England.

(Our reports deliver fact-based news of research and discoveries from around the world.)